Circulation Review Time

For year-over-year citation data, see the Circulation citation metrics page.

Circulation was up from 37.8 in 2023 to 38.6 in 2024. That year-over-year rise matters because it suggests the journal held onto its post-pandemic cardiovascular authority rather than slipping back after the 2021 spike.

Source: AHA Circulation publisher journal metrics + author guidelines (aha.org portal) + SciRev community data; ranges reflect typical bands rather than worst-case outliers.

Three things separate Circulation's review workflow from its two closest competitors, European Heart Journal and JACC.

Format-free first submission. Circulation doesn't require authors to reformat before initial evaluation. You submit the paper in whatever format it currently has, and the editors evaluate it on cardiovascular substance. Reformatting happens only after the paper is invited for revision. This is a real time-saver at the front end, and it also means editors can't use "wrong format" as a soft rejection.

The Clinical Perspective box. This is the single most underestimated part of Circulation's process. Every original research submission must include a short Clinical Perspective with two parts: "What Is New?" and "What Are the Clinical Implications?" Editors read this before anything else. A Clinical Perspective that says something generic like "our findings may have implications for future cardiovascular research" is already losing. The editors want a sentence a cardiologist would repeat to a colleague at a conference.

The current AHA author instructions and article-type guidance reinforce that early filter. Circulation still allows format-free first submission, but it does not relax the requirement to make the clinical consequence legible immediately. That is why the journal can move quickly without feeling administratively shallow.

AHA family triage happens during desk review, not after rejection. At European Heart Journal, a desk rejection is a desk rejection, you resubmit elsewhere yourself. At Circulation, editors actively route papers across the AHA family during triage. A paper that isn't broad enough for the flagship but has genuine cardiovascular merit might get offered a redirect to Circulation Research JIF 18, Circulation: Heart Failure, or Circulation: Arrhythmia and Electrophysiology within the same editorial workflow.

That's not a consolation prize. Circulation Research is a top-5 cardiovascular journal. The redirect saves you weeks of reformatting and resubmitting.

Circulation sits atop an AHA family that includes Circulation Research (basic cardiovascular), Circulation: Heart Failure, Circulation: Arrhythmia and Electrophysiology, Circulation: Cardiovascular Imaging, Circulation: Cardiovascular Interventions, and Circulation: Genomic and Precision Medicine.

This cascade is worth taking seriously. Circulation Research JIF 18 is a top cardiovascular basic science journal. A redirect from the Circulation editorial office often comes with implicit endorsement that speeds up review at the receiving journal.

One tactical point: if your paper is clearly subspecialty (say, a study of left atrial appendage closure outcomes), submitting directly to the relevant specialty title may be faster than submitting to the flagship hoping for a redirect.

Circulation publishes both clinical and translational cardiovascular research, but the editorial balance tilts clinical. Papers that are primarily basic cardiovascular biology (no clinical connection) are usually redirected to Circulation Research. The editorial question is: would a practicing cardiologist change their clinical approach based on this finding?

In practice: a randomized trial of a new anticoagulant strategy is strong Circulation material. A translational biomarker study validated in patient cohorts works if the biomarker could change risk stratification. A mechanistic study of cardiomyocyte calcium handling in a mouse model is Circulation Research territory. An epidemiological cohort study depends on whether the finding is actionable, "exercise prevents heart attacks" won't clear the bar, but identifying a specific modifiable risk factor with clinical implications might.

Days 1-3 (intake): The editorial office confirms your submission is complete. Format-free means this is mostly a check for required elements: manuscript file, Clinical Perspective box, disclosures, data sharing statements. Rarely causes delays.

Days 3-14 (editorial triage): This is where the 17-day median lives. The handling editor reads the Clinical Perspective first, then the abstract, then scans the paper. The question isn't "is this good science?", it's "is this Circulation science?" Papers clearly out of scope get rejected in the first week. Borderline papers take longer because the editor may consult a section editor.

Weeks 2-4 (reviewer recruitment): The hidden bottleneck. Circulation needs 2-3 reviewers who are experts in the specific cardiovascular area AND available within the next month. Niche topics (cardiac amyloidosis imaging, adult congenital heart disease) take longer than mainstream areas (acute coronary syndrome, heart failure).

Weeks 4-8 (peer review): Reviewers typically have 14-21 days. Many request extensions. Circulation reviewers focus heavily on statistical methods, the journal publishes a lot of clinical trials, and the statistical review is rigorous.

Weeks 6-10 (editorial decision): For papers with split opinions, the editor may seek a third review, adding 2-4 weeks. Decision categories: accept (rare on first submission), minor revision, major revision, reject, or reject with redirect to AHA family journal.

Fast desk rejection (1-2 weeks): The cardiovascular significance isn't broad enough for the flagship, or the Clinical Perspective box does not make the consequence concrete quickly enough. Editors may suggest a specialty Circulation title.

AHA family redirect (2-3 weeks): The editors see cardiovascular merit but think a specialty journal is a better fit. This often comes with a recommendation that helps at the receiving journal. Accept the redirect promptly, sitting on it doesn't help.

Review taking 6+ weeks: Normal. Cardiovascular specialists are busy clinician-scientists with patient care responsibilities. The AHA conference season (November) and ACC meeting season (March) slow things down predictably.

Revision focused on clinical implications or statistics: Common. Editors want clinical relevance made explicit, even for translational papers. Statistical revision requests (sensitivity analyses, subgroup analyses, missing data handling) are also frequent, Circulation's statistical review standards are high.

Keep follow-ups short: manuscript ID, submission date, single sentence asking about status.

The Manusights Circulation readiness scan. This guide tells you what Circulation (American Heart Association)'s editors look for in the first 1-2 weeks of triage. The review tells you whether your paper passes that check before you submit.

We have reviewed manuscripts targeting Circulation (American Heart Association) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages. documented review timeline of approximately 7-10 days for desk-screen. 60-day money-back guarantee. We do not train AI on your manuscript and delete it within 24 hours.

For Circulation-targeted manuscripts, three patterns most consistently predict slow review at Circulation (American Heart Association). Of manuscripts we screened in 2025 targeting Circulation and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: Circulation editors enforce practice-changing-evidence threshold; mechanistic papers without immediate clinical-translation pathway get desk-rejected within 7-10 days.

Scope-fit ambiguity in the abstract. Circulation editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (cardiovascular research with practice-changing implications for working cardiologists). The named failure pattern: mechanistic papers without clinical-translation pathway get desk-rejected within 7-10 days. Check whether your abstract reads to Circulation's scope →

Methods package incomplete for the journal's reviewer pool. Circulation reviewers expect specific methodological detail. Trials with pre-specified primary endpoint not matching headline finding extend revision. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Circulation (American Heart Association) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: AHA journal page. Manuscript constraints: 350-word abstract limit and 5,000-word main-text cap (Circulation enforces during desk-screen).

We reviewed each of these constraints against current journal author guidelines (accessed 2026-05-08); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Circulation (American Heart Association). Of the manuscripts our team screened before submission to Circulation and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Circulation editors enforce practice-changing-evidence threshold; mechanistic papers without immediate clinical-translation pathway get desk-rejected within 7-10 days.

In our analysis of anonymized Circulation-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear Circulation's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.